Trial Profile
A Randomized, Controlled, Observer-blind, Phase 1/2a Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.RSV.preF in RSV-seronegative Toddlers 12 to 24 Months of Age
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Nov 2023
Price :
$35
*
At a glance
- Drugs JNJ 64400141 (Primary) ; Meningococcal vaccine groups A B C Y W-135 conjugate
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions
- Sponsors Janssen Vaccines and Prevention B.V
- 23 Nov 2021 Status changed from active, no longer recruiting to completed.
- 11 Nov 2021 This trial has been completed in Poland, according to European Clinical Trials Database record.
- 26 Oct 2021 Planned End Date changed from 31 Oct 2021 to 1 Nov 2021.